Literature DB >> 7768395

Exacerbation of chronic ulcerative colitis with mesalamine.

J B Sturgeon1, P Bhatia, D Hermens, P B Miner.   

Abstract

Activation of ulcerative colitis with mesalamine has rarely been reported. In case 1, a 34-year-old man was treated with oral mesalamine, resulting in an exacerbation of colitis that rapidly improved with glucocorticoids and mesalamine withdrawal. Oral cromolyn sodium and occasional low-dose prednisone therapy has maintained long-term remission. In case 2, a 28-year-old man receiving prednisone treatment developed chest pain and myalgias 1 week after initiation of mesalamine that resolved on mesalamine withdrawal. A lower dose of mesalamine with continued glucocorticoids resulted in clinical improvement, and both drugs were tapered. Mesalamine sensitivity was documented endoscopically and histologically by evaluating mucosal changes after two mesalamine enemas during a 24-hour period. There was dramatic progression from quiescent disease to active colitis in 24 hours. Mesalamine sensitivity must be included in the differential diagnosis of ulcerative colitis exacerbations. Concurrent steroid therapy can suppress systemic side effects, making the diagnosis even more elusive.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768395     DOI: 10.1016/0016-5085(95)90154-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

Review 1.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

2.  Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion.

Authors:  Maneesh Kumar Gupta; Scott Pollack; John J Hutchings
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-12-06

3.  Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance.

Authors:  Koichi Soga; Kenji Itani
Journal:  Clin J Gastroenterol       Date:  2019-04-29

4.  Ketotifen therapy for acute ulcerative colitis in children: a pilot study.

Authors:  N L Jones; C M Roifman; A M Griffiths; P Sherman
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

5.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 6.  Strategies for the care of adults hospitalized for active ulcerative colitis.

Authors:  Suresh Pola; Derek Patel; Sonia Ramamoorthy; Elisabeth McLemore; Marianne Fahmy; Jesus Rivera-Nieves; John T Chang; Elisabeth Evans; Michael Docherty; Mark Talamini; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-24       Impact factor: 11.382

7.  Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.

Authors:  Hao Ding; Xiao-Chang Liu; Qiao Mei; Jian-Ming Xu; Xiang-Yang Hu; Jing Hu
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

8.  A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions.

Authors:  Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Terasu Honma; Yoichi Ajioka; Shogo Ohkoshi
Journal:  Am J Case Rep       Date:  2018-05-31

9.  5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis.

Authors:  Jun Miyoshi; Katsuyoshi Matsuoka; Atsushi Yoshida; Makoto Naganuma; Tadakazu Hisamatsu; Tomoharu Yajima; Nagamu Inoue; Susumu Okamoto; Yasushi Iwao; Haruhiko Ogata; Fumiaki Ueno; Toshifumi Hibi; Takanori Kanai
Journal:  Intest Res       Date:  2018-10-10

10.  Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.

Authors:  Rumiko Tsuboi; Satohiro Matsumoto; Hiroyuki Miyatani; Hirosato Mashima
Journal:  Intern Med       Date:  2018-10-17       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.